Logo image of GENT.OL

GENTIAN DIAGNOSTICS ASA (GENT.OL) Stock Price, Quote, News and Overview

OSL:GENT - Euronext Oslo - NO0010748866 - Common Stock - Currency: NOK

49.5  -0.5 (-1%)

GENT.OL Quote, Performance and Key Statistics

GENTIAN DIAGNOSTICS ASA

OSL:GENT (4/25/2025, 7:00:00 PM)

49.5

-0.5 (-1%)

Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Supplies
Statistics
52 Week High61
52 Week Low36
Market Cap763.29M
Shares15.42M
Float9.64M
Yearly DividendN/A
Dividend Yield0.85%
PE17.13
Fwd PE27.26
Earnings (Next)N/A N/A
IPO12-14 2016-12-14


GENT.OL short term performance overview.The bars show the price performance of GENT.OL in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 5 10 15

GENT.OL long term performance overview.The bars show the price performance of GENT.OL in the last 1, 2 and 3 years. 1 year 2 years 3 years 10 20 30

The current stock price of GENT.OL is 49.5 NOK. In the past month the price increased by 6.68%. In the past year, price increased by 34.51%.

GENTIAN DIAGNOSTICS ASA / GENT Daily stock chart

GENT.OL Competitors/Peers

The largest stocks on the EU markets in the "Health Care Supplies" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ESL.DE ESSILORLUXOTTICA 37.35 116.02B
EL.PA ESSILORLUXOTTICA 37.3 115.89B
1EL.MI ESSILORLUXOTTICA 37.1 115.25B
CBHD.DE COLOPLAST-B 33.08 20.44B
GBT.PA GUERBET 14.94 239.91M
PTP.DE PENTIXAPHARM HOLDING AG N/A 72.04M
AFME.PA AFFLUENT MEDICAL SA N/A 52.34M
ALCJ.PA CROSSJECT N/A 40.68M

About GENT.OL

Company Profile

GENT logo image Gentian Diagnostics ASA engages in the research, development, production, marketing, and distribution of immunoassays. The company is headquartered in Moss, Ostfold. The company went IPO on 2016-12-14. The firm develops and manufactures in vitro diagnostic (IVD) products for the detection and quantification of specific markers for use on a wide range of clinical chemistry analysers. The Company’s product portfolio comprises turbidimetric fecal calprotectin immunoassay, which is to be run on clinical chemistry analysers: The Gentian Calprotectin Immunoassay, Cystatin C, NT-proBNP - Pre-launch, SARS-CoV-2 Ab Pre-Launch, Canine CRP and Beckman Coulter Customers. The firm is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China.

Company Info

GENTIAN DIAGNOSTICS ASA

Bjornasveien 5

Moss OSTFOLD NO

Employees: 58

Company Website: https://www.gentian.com/

Investor Relations: http://www.gentian.com/investor-relation

Phone: 4799339905

GENTIAN DIAGNOSTICS ASA / GENT.OL FAQ

What is the stock price of GENTIAN DIAGNOSTICS ASA today?

The current stock price of GENT.OL is 49.5 NOK. The price decreased by -1% in the last trading session.


What is the ticker symbol for GENTIAN DIAGNOSTICS ASA stock?

The exchange symbol of GENTIAN DIAGNOSTICS ASA is GENT and it is listed on the Euronext Oslo exchange.


On which exchange is GENT.OL stock listed?

GENT.OL stock is listed on the Euronext Oslo exchange.


What is the price forecast or stock price prediction for GENTIAN DIAGNOSTICS ASA stock?

7 analysts have analysed GENT.OL and the average price target is 68.34 NOK. This implies a price increase of 38.06% is expected in the next year compared to the current price of 49.5. Check the GENTIAN DIAGNOSTICS ASA stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is GENTIAN DIAGNOSTICS ASA worth?

GENTIAN DIAGNOSTICS ASA (GENT.OL) has a market capitalization of 763.29M NOK. This makes GENT.OL a Small Cap stock.


How many employees does GENTIAN DIAGNOSTICS ASA have?

GENTIAN DIAGNOSTICS ASA (GENT.OL) currently has 58 employees.


What are the support and resistance levels for GENTIAN DIAGNOSTICS ASA (GENT.OL) stock?

GENTIAN DIAGNOSTICS ASA (GENT.OL) has a support level at 47.59 and a resistance level at 49.63. Check the full technical report for a detailed analysis of GENT.OL support and resistance levels.


Is GENTIAN DIAGNOSTICS ASA (GENT.OL) expected to grow?

The Revenue of GENTIAN DIAGNOSTICS ASA (GENT.OL) is expected to grow by 33.11% in the next year. Check the estimates tab for more information on the GENT.OL EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy GENTIAN DIAGNOSTICS ASA (GENT.OL) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does GENTIAN DIAGNOSTICS ASA (GENT.OL) stock pay dividends?

GENTIAN DIAGNOSTICS ASA (GENT.OL) has a dividend yield of 0.85%. The yearly dividend amount is currently 0. Check the full fundamental report for a detailed analysis of GENT.OL dividend history, reliability and sustainability.


What is the Price/Earnings (PE) ratio of GENTIAN DIAGNOSTICS ASA (GENT.OL)?

The PE ratio for GENTIAN DIAGNOSTICS ASA (GENT.OL) is 17.13. This is based on the reported non-GAAP earnings per share of 2.89 and the current share price of 49.5 NOK. Check the full fundamental report for a full analysis of the valuation metrics for GENT.OL.


GENT.OL Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to GENT.OL. When comparing the yearly performance of all stocks, GENT.OL is one of the better performing stocks in the market, outperforming 85.12% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

GENT.OL Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to GENT.OL. GENT.OL is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

GENT.OL Financial Highlights

Over the last trailing twelve months GENT.OL reported a non-GAAP Earnings per Share(EPS) of 2.89. The EPS increased by 522.84% compared to the year before.


Industry RankSector Rank
PM (TTM) 29.78%
ROA 19.72%
ROE 23.34%
Debt/Equity 0.03
Chartmill High Growth Momentum
EPS Q2Q%422.94%
Sales Q2Q%13.73%
EPS 1Y (TTM)522.84%
Revenue 1Y (TTM)12.52%

GENT.OL Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 86% to GENT.OL. The Buy consensus is the average rating of analysts ratings from 7 analysts.

For the next year, analysts expect an EPS growth of 76.24% and a revenue growth 33.11% for GENT.OL


Ownership
Inst Owners30.99%
Ins Owners2.59%
Short Float %N/A
Short RatioN/A
Analysts
Analysts85.71
Price Target68.34 (38.06%)
EPS Next Y76.24%
Revenue Next Year33.11%